LQDA Stock Forecast & Price Target

Liquidia is favorably positioned because the global settlement with United Therapeutics removes the most meaningful legal overhang, keeps YUTREPIA on the market with a PAH label, and gives management freedom to focus on a core franchise that already represents roughly three-quarters of branded prostacyclin sales. The commercial evidence is encouraging: preliminary 3Q26 YUTREPIA sales of $222.7 million beat consensus and were up 31% sequentially and 331% year over year, supporting the view that the product can continue gaining share even after PH-ILD is removed from the label. In addition, the company’s pipeline offers multiple shots on goal, with L606 providing a differentiated liposomal treprostinil opportunity and studies in PAH, IPF/PPF, and other settings preserving longer-term growth potential.

Liquidia is facing a challenging commercial path because Yutrepia competes directly against entrenched PAH therapies from larger, better-capitalized players such as United Therapeutics and Actelion, including Tyvaso and Tyvaso DPI. The company also depends on third parties to manufacture Yutrepia and to potentially expand ex-U.S. commercialization, which adds execution risk and reduces control over supply and strategic rollout. Fundamentally, it will require substantial capital to fund the commercialization of Yutrepia and L606, and the prospect of rising operating expenses and future dilutive financings weighs on the investment case.